The Architect's Retirement After Completing a 10-Year R&D Transformation

Andy Plump, President of R&D who has led the Research and Development division at Takeda Pharmaceutical (TAK) for the past 10 years, is scheduled to retire in June 2027. Having joined in 2015, he is evaluated as the key architect who transformed Takeda from a traditional Japanese pharmaceutical company into a global innovative biopharmaceutical. He transplanted Celgene’s aggressive external technology acquisition model, establishing numerous R&D collaboration networks with promising biotechs. Notably, he made a decisive move to significantly expand the Rare Disease portfolio by leading the $62 billion acquisition of Shire in 2019.

Achieving Structural Improvement Despite Clinical Failures and Restructuring

Takeda's 10-year journey was not always smooth, as it had to endure numerous pipeline setbacks and business reorganizations. The company completely halted its ambitious cell therapy research and faced painful setbacks, including the voluntary withdrawal of the non-small cell lung cancer treatment Exkivity (mobocertinib) and the withdrawal of the US marketing authorization application for the dengue vaccine Qdenga. Furthermore, due to the Loss of Exclusivity (LOE) of the flagship blockbuster ADHD treatment Vyvanse, the company implemented restructuring involving thousands of employees. However, he turned the crisis of pipeline losses and cost reduction into an opportunity, completely reorganizing the R&D process into a high-efficiency-centered system.

The Three Next-Generation Blockbusters Worth $8 Billion Yield Fruitful Results

The Open Innovation strategy built by CEO Plump is finally bearing explosive commercial results just as he departs. In August 2026, Takeda sequentially obtained US FDA approvals for Orzeyful (oveporexton), a narcolepsy type 1 treatment based on an orexin receptor 2 agonist (OX2R Agonist), and Mimrylo (rusfertide), a polycythemia vera (PV) treatment licensed from Protagonist. Additionally, Zasocitinib (TAK-279), an oral allosteric tyrosine kinase 2 (TYK2) inhibitor acquired from Nimbus with a $4 billion upfront payment, has demonstrated overwhelming efficacy in Phase 3 clinical trials for psoriasis compared to competing drugs and is preparing to submit a New Drug Application (NDA) within the year. Jefferies Securities analyzes that the combined peak annual sales potential of these three new drugs could reach over $8 billion.

Ensuring Systemic Continuity and Challenges for Next-Generation Leadership

CEO Julie Kim dismissed market concerns, stating that Plump has built a sustainable R&D foundation that does not rely on any specific individual. President Plump plans to oversee operations until a successor is confirmed, then complete a smooth handover and remain on the Board of Directors to coordinate the organization's strategic direction through the regular general shareholders' meeting in June 2027. Now, Takeda's next R&D leadership faces a critical test in maximizing commercial success by leading the successful global launch and indication expansion of its three blockbuster drugs.